Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Ugeskr Laeger. 2006 Nov 20;168(47):4098-101.

[Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial--secondary publication].

[Article in Danish]

Author information

  • 1Odense Universitetshospital, Endokrinologisk og Nuklearmedicinsk Afdeling, Odense C. viveque.egsgaard@ouh.fyns-amt.dk


In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk